Aberdeen Group
MRNA icon

Aberdeen Group’s Moderna MRNA Stock Holding History

Aberdeen Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Sell
14,995
-2,956
-16% -$153K ﹤0.01% 831
2026
Q1 		$912K Sell
17,951
-1,274
-7% -$59.4K ﹤0.01% 831
2025
Q4 		$567K Hold
19,225
– – ﹤0.01% 875
2025
Q3 		$497K Sell
19,225
-62,274
-76% -$1.74M ﹤0.01% 894
2025
Q2 		$2.25M Buy
81,499
+1,482
+2% +$39K ﹤0.01% 774
2025
Q1 		$2.27M Sell
80,017
-235,895
-75% -$8.37M ﹤0.01% 750
2024
Q4 		$12.8M Buy
315,912
+69,360
+28% +$3.32M 0.02% 464
2024
Q3 		$16.3M Sell
246,552
-46,110
-16% -$4.23M 0.03% 432
2024
Q2 		$34.8M Sell
292,662
-170,452
-37% -$21.6M 0.07% 267
2024
Q1 		$49.3M Sell
463,114
-20,460
-4% -$2.06M 0.1% 221
2023
Q4 		$48.1M Buy
483,574
+399,843
+478% +$33.6M 0.1% 212
2023
Q3 		$8.65M Sell
83,731
-5,374
-6% -$599K 0.02% 473
2023
Q2 		$10.8M Sell
89,105
-3,509
-4% -$468K 0.03% 461
2023
Q1 		$14.2M Sell
92,614
-1,527
-2% -$252K 0.04% 401
2022
Q4 		$16.9M Buy
94,141
+8,061
+9% +$1.32M 0.05% 367
2022
Q3 		$10.2M Sell
86,080
-15,293
-15% -$2.32M 0.03% 428
2022
Q2 		$14.6M Sell
101,373
-1,025
-1% -$147K 0.05% 353
2022
Q1 		$17.9M Sell
102,398
-15,161
-13% -$2.55M 0.05% 326
2021
Q4 		$29.9M Sell
117,559
-5,048
-4% -$1.48M 0.07% 271
2021
Q3 		$47.2M Buy
122,607
+90,699
+284% +$33.5M 0.11% 197
2021
Q2 		$7.5M Buy
31,908
+74
+0.2% +$13.2K 0.02% 565
2021
Q1 		$4.17M Buy
31,834
+457
+1% +$66.2K 0.01% 679
2020
Q4 		$3.28M Buy
31,377
+2,855
+10% +$289K 0.01% 680
2020
Q3 		$2.02M Buy
28,522
+12,695
+80% +$885K 0.01% 704
2020
Q2 		$1.02M Buy
+15,827
New +$867K ﹤0.01% 776

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Aberdeen Group's MRNA Position: Q2 2026 in Review

Aberdeen Group reduced its Moderna (MRNA) stake by 16% in Q2 2026, selling an estimated $153K and leaving 14,995 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #831.

Aberdeen Group first reported a position in MRNA in Q2 2020 and has held it in 25 quarters since. The position peaked at $49.3M in Q1 2024. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Aberdeen Group held 14,995 shares of Moderna worth $1.05M as of Q2 2026.
  • Aberdeen Group sold 2,956 Moderna shares in Q2 2026, an estimated $153K.
  • Moderna made up ﹤0.01% of Aberdeen Group's portfolio in Q2 2026, its #831 holding.
  • Aberdeen Group first reported a position in Moderna in Q2 2020 and has held it in 25 quarters since.
  • Aberdeen Group's Moderna position peaked at $49.3M in Q1 2024.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.